Defy Medical, MD

Defy Medical is a Tampa, Florida-based hormone and integrative medicine clinic founded in 2012 that has grown into one of the most recognized names in the direct-pay men's health space. The company operates a hybrid model: an in-person clinic at its Tampa headquarters, where patients can receive IV infusions, injections, and in-office procedures, alongside a full national telemedicine practice that allows it to serve patients across the country regardless of geography. The clinical scope at Defy is unusually wide for a telehealth-accessible clinic. Beyond testosterone replacement therapy, Defy physicians prescribe HGH peptides including sermorelin, ipamorelin, CJC-1295, BPC-157, and tesamorelin — therapies that most primary care physicians are unfamiliar with and that require specialized clinical oversight. The clinic also offers thyroid optimization, erectile dysfunction protocols (including P-shot and GAINSWave at the Tampa location), weight loss programs, ketamine therapy, nutrient IV infusions, and aesthetic services. This breadth reflects the company's positioning as a one-stop shop for men who want to actively manage their health rather than simply treat symptoms as they arise. Defy's pricing model is deliberately unbundled. Rather than charging a flat monthly membership fee, patients are billed for each protocol component — consultation, labs, medications, and supplies — separately. This transparency appeals to patients who want to understand exactly what they are paying for, but it can make cost comparisons with subscription competitors difficult. A patient on a basic TRT-only protocol should expect to spend $200–$350 per month all-in; a patient on a comprehensive stack including testosterone, a GH peptide, and ancillary medications can expect $400–$650 per month or more. The clinical team is led by medical directors with fellowship training in age management and preventive medicine, and the company has invested heavily in physician education around emerging protocols. Defy operates as an entirely cash-pay practice — it does not accept insurance — which is both a feature and a limitation: patients gain access to treatments that insurance would typically deny, but they bear the full cost without reimbursement. Regulatory headwinds have affected some services. Following the FDA's removal of semaglutide from the shortage list in early 2025, compounded GLP-1 pathways became more complex, and patients interested in weight-loss medications should confirm current availability directly with the clinic. Despite these pressures, Defy remains one of the few telehealth-accessible clinics where patients can discuss and receive a full spectrum of peptide and hormone protocols in a single relationship, without the referral chains or formulary restrictions of conventional medicine. The company operates a hybrid model: an in-person clinic at its Tampa headquarters, where patients can receive IV infusions, injections, and in-office procedures, alongside a full national telemedicine practice that allows it to serve patients across the country regardless of geography. The clinical scope at Defy is unusually wide for a telehealth-accessible clinic. Beyond testosterone replacement therapy, Defy physicians prescribe HGH peptides including sermorelin, ipamorelin, CJC-1295, BPC-157, and tesamorelin — therapies that most primary care physicians are unfamiliar with and that require specialized clinical oversight. The clinic also offers thyroid optimization, erectile dysfunction protocols (including P-shot and GAINSWave at the Tampa location), weight loss programs, ketamine therapy, nutrient IV infusions, and aesthetic services. This breadth reflects the company's positioning as a one-stop shop for men who want to actively manage their health rather than simply treat symptoms as they arise. Defy's pricing model is deliberately unbundled. Rather than charging a flat monthly membership fee, patients are billed for each protocol component — consultation, labs, medications, and supplies — separately. This transparency appeals to patients who want to understand exactly what they are paying for, but it can make cost comparisons with subscription competitors difficult. A patient on a basic TRT-only protocol should expect to spend $200–$350 per month all-in; a patient on a comprehensive stack including testosterone, a GH peptide, and ancillary medications can expect $400–$650 per month or more. The clinical team is led by medical directors with fellowship training in age management and preventive medicine, and the company has invested heavily in physician education around emerging protocols. Defy operates as an entirely cash-pay practice — it does not accept insurance — which is both a feature and a limitation: patients gain access to treatments that insurance would typically deny, but they bear the full cost without reimbursement. Regulatory headwinds have affected some services. Following the FDA's removal of semaglutide from the shortage list in early 2025, compounded GLP-1 pathways became more complex, and patients interested in weight-loss medications should confirm current availability directly with the clinic. Despite these pressures, Defy remains one of the few telehealth-accessible clinics where patients can discuss and receive a full spectrum of peptide and hormone protocols in a single relationship, without the referral chains or formulary restrictions of conventional medicine.